Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29034)	7/7/1999 9:00:00 AM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

henry, this is old news and was reported months ago involving elan and others.Has to do with how they report earnings and R&D.

To: Henry Niman who wrote (29034)	7/7/1999 4:50:00 PM
From: Cheryl Galt	Respond to of 32384

Hi Henry! On another thread today, Ike posted the transcript of an interesting Pharma/biotech interview - a mixture of facts, opinions, recs, and cautions. Gruntal & Co.'s David Saks (Gruntal's senior pharmaceuticals analyst. ) 6/29/99 interview on AOL Live - MarketTalk, hosted by Sage IMO, here's the most important part of interview -- given AOL's wide audience (plus promotion by a respected SI contributor): Saks downplayed the Clinton "Medicare Scare." SAKS: President Clinton's proposals are only proposals, and for the past 20 years the industry has experienced growth every year with increased regulation. I see more growth, more demand, and very little chance, in my judgment, of government interference. Those concerns have been there a long time and never slowed growth. In fact, government assistance has produced more new drugs, more growth, and greater shareholder wealth. There is nothing to fear, in my judgment. (TA enthusiasts might like to keep an eye on the Stochastics of the depressed pharma stocks.) ----------------------------------------- Saks likes - PFE - (poised to have one of the best lineups of new products launched and of new products with blockbuster potential. We expect Pfizer to report all-time-record earnings this year and into the next several years. ) - WLA - (the fastest growing blue-chip drug company in the market. Rezulin problems already discounted in the share price.) - SGP and AHP (They have high biotech components yet blue-chip financial strength.) - LLY - (outlook short and long term is outstanding.) Saks sees lots of new products. Mentions Actos and Zyprexa) - AMGN and BGEN - (the leading companies in the field. Amgen faces fabulous earnings near term and a bigger-than-ever pipeline) - Ivax - (IVX) - Gruntal's new featured BUY recommendation. We see a major earnings turnaround at IVAX ... new-product story in generics, cancer, asthma) - JNJ - (would be my favorite stock for the growth investor who wants a security blanket of growth in healthcare and drugs.) LOL! - SBH - (The recent sale of its non-drug operations brought in billions of dollars that can be redeployed in new areas.) Saks notes currency volatility concern. Saks mentions biotech in general. (He doesn't mention LGND or ELN) Saks likes Andrx (ADRX) and SEPR (Prefers ADRX) Complete transcript at IKE's Idea 27419 - Message 10407561 Regards, Cheryl PS -- How do you like the SI Beta ??!! I especially like the ability to see the next/previous 10 posts. That makes it quick to read several useful posts, while ignoring the chaff. No more w a i t i n g for the <Next> button to repaint the screen. Imo, it obsoletes any need for a goof-ball filter ... -- a nice non-confrontational First-Amendment-friendly solution!